UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

PROTECTIVE EFFECTS OF STW 5 AGAINST CHANGES IN THE MICROBIOME IN AN EXPERIMENTAL MODEL OF FUNCTIONAL DYSPEPSIA

Mohamed T. Khayyal 1, Olaf Kelber 2, Aziz-Kalbhenn Heba 2

Affiliations

1 Faculty of Pharmacy, Cairo University, Cairo, Egypt

2 Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany

Summary

AI Generated

A preclinical rat study examined whether STW 5, a herbal medicinal product, could prevent stress-induced gut microbiota changes in an experimental model of functional dyspepsia.

Functional dyspepsia was induced in rats through neonatal maternal separation followed by one week of daily 90-minute restraint stress, and one group received liquid STW 5 (5 ml/kg) during the stress week while another received vehicle.
The stress model produced a 50% drop in Lactobacilli population, a two-fold rise in Proteobacteria abundance, a more than two-fold increase in Methanobrevibacter, and a near-complete depletion of Bifidobacterium genomic DNA (from approximately 3 ng/g feces to nearly nil).
STW 5 treatment tended to ameliorate and protect against the microbiota changes induced by the stress model, including at least partial antagonism of changes in lactobacilli.
The authors conclude that the findings lend further support to the use of STW 5 in functional dyspepsia and irritable bowel syndrome by providing evidence it acts at least in part through beneficially influencing stress-induced changes in intestinal microbiota.
The study may be of interest to researchers investigating herbal treatments for disorders of gut-brain interaction and the role of microbiota in functional gastrointestinal disorders.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

STW 5, a herbal medicinal product with well characterized pharmacological action, has been shown in several RTCs to be an effective treatment in disorders of the gut-brain interaction (DGBI) as functional dyspepsia (FD) [1, 2]. The aim of the present study was to examine whether changes in gut microbiota induced in an experimental model of FD could be prevented by STW 5.

Aims & Methods

FD was induced in rats by subjecting them to neonatal maternal separation followed by subjecting them to restraint stress for 90 minutes/day for one week. During that week, one group (8 animals) was treated with the liquid form of STW 5 (5 ml/Kg) and one with its vehicle at the same dose level. Animals were sacrificed 24 h after the last drug administration. Fecal samples were taken from the cecum. Genomic DNA was isolated and changes in selected bacterial phyla and genera were assessed using quantitative Real Time-PCR (qPCR). The main phyla studied under the influence of stress in the model were the Bacteroidetes, Firmicutes, Fusibacterium and Actinobacteria.

Results

FD led to a 50% drop in the Lactobacilli population but to a two-fold rise in Proteobacteria abundance but did not affect significantly the changes in Bacteroidetes. Furthermore, the Methanobrevibacter population was raised more than two-fold while the genomic DNA concentration in Bifidobacterium dropped from ca. 3 ng/g feces to nearly nil.

Conclusion

In general, STW 5 tended to ameliorate and protect against the changes induced by the stress model. The results lend further support to the use of STW 5 in FD and IBS by providing evidence that it acts at least in part through influencing beneficially the changes in intestinal microbiota induced by stress. Taken together, the findings shed more light on mechanisms involved in the therapeutic action of STW 5 in gastro-intestinal disorders.

References

1. Malfertheiner P. STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders. Dig Dis. 2017, 35 Suppl 1: 25-29
2. Allescher H-D, Burgell R, Malfertheiner P, Mearin F. Multi-target Treatment for Irritable Bowel Syndrome with STW 5: Pharmacological Modes of Action. Gastrointest Liver Dis. 2020;29: 227-233

Disclosure

OK and HA-K are empolyees of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany. MTK has been obtaining travel support and speakers fees from Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany.

Conference

UEG Week Berlin 2025

Topics

Oesophagus

Submission format

Abstract

Session

OESOPHAGEAL, GASTRIC AND DUODENAL (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jolanta Lorentzen 1, Jostein W. Hauge 2, Asle W. Medhus 3, Jens K. Hertel 2, Birgitte Seip 4, Marius Svanevik 2, Rune Sandbu 2, Dag Hofsø 2, Jøran Hjelmesæth 2

Affiliations

1 Vestfold Hospital Trust, Tønsberg, Norway

2 Vestfold Hospital Trust, Tonsberg, Norway

3 Oslo University Hospital, Oslo, Norway

4 Vestfold Hospital, Tønsberg, Norway

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Few studies have examined esophageal motility disorders in patients with type 2 diabetes operated with sleeve gastrectomy (SG) or gastric bypass (RYGB).

Aims & Methods

We have recently reported overall prevalence of gastroesophageal reflux disease (GERD) in this group of patients (1) and now aimed to investigate potential differences between the two surgical methods regarding the prevalence of dysmotility 5 years after surgery. Furthermore, we also aimed to analyse and report on the available GERD-data in detail.
In the Oseberg study (January 2013 – December 2022), 125 patients with BMI ≥ 35 kg/m² and type 2 diabetes were screened, sixteen patients were excluded or withdrew consent, leaving 109 patients allocated to SG (n=55) or RYGB (n=54). To assess reflux symptoms, GerdQ (Gastroesophageal reflux disease questionnaire) was completed. Gastroscopy and 24-hour pH monitoring were used to examine GERD. High-resolution manometry with the Chicago classification v3.0 was used to assess esophageal motility.

Results

At inclusion the average age was 47.7 years (SD 9.6), BMI was 42.3 kg/m2 (5.3), and 66% were women. At the 5-year follow-up, 29 (53%) patients in SG-group and 32 (59%) in RYGB-group underwent gastroscopy, 22 (40%) vs. 25 (46%) underwent 24-hour pH monitoring, 23 (42%) vs. 26 (48%) underwent manometry, and 42 (76%) vs. 42 (78%) completed GerdQ. The proportion of patients with GERD symptoms (GerdQ ≥8) was low in both groups, with a slightly lower prevalence after RYGB (2%) than after SG (14%). There was no difference in the prevalence of erosive esophagitis between the groups (38% in SG and 41% in RYGB), all findings with less advanced esophagitis (Los Angeles grades A and B), but one patient in each group had new onset Barrett's esophagus. The proportion of patients with pH<4 for more than 6% of the recording (Acid exposure time, AET) was significantly higher after SG compared with RYGB (59% versus 8%, p < 0.0001). Esophageal dysmotility was diagnosed in 14 (61%) after SG compared with 19 (73%) patients after RYGB. Most of these patients (n=22) had hypertensive or hypotensive lower esophageal sphincter (LES), with no difference between groups. The remaining 11 patients had ineffective esophageal motility (IEM) or elevated distal contractile integral (DCI). None of the patients with dysmotility reported swallowing difficulties or chest pain with food intake.

Conclusion

The Oseberg study demonstrates a high prevalence of asymptomatic esophageal dysmotility after SG or RYGB with uncertain clinical relevance. Furthermore, a seven times higher prevalence of pathological acid reflux after SG compared with RYGB was demonstrated, but the prevalences of erosive esophagitis and esophageal dysmotility were approximately similar between groups. Few of the examined patients reported GERD symptoms, hence objective assessment of GERD should be included in long-term follow-up after SG to detect and prevent the development of Barrett's esophagus, dysplasia, and adenocarcinoma.

References

1. Hauge JW et al., Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2025 Apr 1:S2213-8587(24)00396-6

Event

UEG Week Berlin 2025

Topics

Neurogastroenterology & Motility Oesophagus

Submission format

Abstract

Session

Burning issues in GERD

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

GP: First line diagnosis and treatment

Juan Mendive 1

Affiliations

1 European Society for Primary Care Gastroenterology (ESPCG), Sant Adrià de Besòs ( Barcelona), Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Neurogastroenterology & Motility Primary Care

Session

Therapy update: Dyspepsia

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Whole diet interventions for IBS

Heidi Staudacher 1

Affiliations

1 The University of Queensland, Melbourne, Australia

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

IBD Neurogastroenterology & Motility Primary Care

Session

Diet and disorders of gut-brain interaction: From IBS to IBD

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

The diagnosis

Bruce E. Sands 1

Affiliations

1 Icahn School of Medicine at Mount Sinai, New York, United States of America

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

IBD Primary Care

Session

When IBD and IBS experts collaborate for optimal diagnosis and treatment of IBD with IBS-like symptoms

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Alexandros Tsoposidis 1, Srdjan Kostic 1, Lars Lundell 2, Ville Wallenius 1, Hans Axelsson 1, Anders Thorell 3, Bengt Håkanson 3, Marcus Reuterwall Hansson 3

Affiliations

1 University of Gothenburg, Gothenburg, Sweden

2 Karolinska Institutet, Stockholm, Sweden

3 Karolinska Institutet, Stockholm, Sweden|||Ersta Hospital, Stockholm, Sweden

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

The optimal surgical approach to reduce recurrence rates after laparoscopic repair of paraesophageal hernia (PEH) is yet to be defined. The crural repair is challenged by both axial and transverse-lateral tension, which may compromise durability. The aim of this double-blind randomized clinical trial was to investigate whether a left-sided diaphragmatic relaxing incision in addition to standard crural repair and fundoplication reduces anatomical recurrence rates at one year postoperatively.

Aims & Methods

This study was conducted at two high-volume Swedish centers—Ersta Hospital (Stockholm) and Sahlgrenska University Hospital (Gothenburg)—between August 2019 and August 2023. Adult patients undergoing surgery for PEH were randomized 1:1 to either standard crural repair with total (360°) fundoplication (control) or the same procedure with the addition of a left-sided diaphragmatic relaxing incision covered by synthetic mesh (intervention). Patients with prior hiatal surgery, ASA class IV or above, type I hernia, major esophageal motility disorders, or any contraindication to fundoplication were excluded. Blinding for patients and assessors was maintained throughout follow-up. Pre- and postoperative assessments included computed tomography (CT), symptom questionnaires (Dakkak dysphagia score, Gastrointestinal Symptom Rating Scale [GSRS]), and quality of life (QoL, RAND-36). The primary outcome was radiologically confirmed PEH recurrence at 12 months.

Results

Of 103 patients screened, 76 were randomized (38 per group). Baseline characteristics were well balanced. CT was completed in 72 patients (95%) at 12 months. The recurrence rate was 66% in the control group and 54% in the intervention group (p=0.313). Three patients in the intervention group had asymptomatic CT verified herniation at the site of the diaphragmatic incision. There were no differences in recurrence size distribution (<4 cm vs >4 cm) between groups. Postoperative symptom assessment revealed significant improvements in dysphagia, reflux, indigestion, and abdominal pain in both groups, without intergroup differences. Physical QoL (PCS) improved significantlywhereas mental QoL (MCS) remained unchanged. Two deaths occurred within 90 days postoperatively (1 per group), yielding a 90-day mortality of 2.6%. Other complications included mediastinal abscess (n=1, intervention group) and need for postoperative endoscopic dilatation (n=5 in total). Operation time tended to be longer in the intervention group (150 vs 133 min; p=ns).

	Crural repair alone	Crural repair with relaxing diaphragmatic incision	P value
Completed CT chest at 1 year	35/38	37/38
Radiological recurrence	23 (66%)	20 (54%)	.313
Recurrence<4cm	12 (34%)	11 (30%)	.522
Recurrence>4cm	11 (31%)	9 (24%)	.457

Table 1: Radiological recurrences 1 year after surgical repair of PEH

Conclusion

In this randomized, double-blind trial, the addition of a left-sided diaphragmatic relaxing incision to standard laparoscopic PEH repair did not improve anatomical recurrence rates, symptom relief or QoL at 12 months after surgery and should not be recommended for routine use. Alternative strategies to improve recurrence rates after PEH need to be explored in the future.

Event

UEG Week Berlin 2025

Topics

Neurogastroenterology & Motility Oesophagus

Submission format

Abstract

Session

Burning issues in GERD

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Robert-Jan Pierik 1, Lauranne Derikx 1, Jildou Hoekstra 2, Richard Post 1, Rosanne van Dongen 2, Annemarie de Vries 1, Alexander Bodelier 2

Affiliations

1 Erasmus University Medical Center, Rotterdam, Netherlands

2 Amphia Hospital, Breda, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Ulcerative proctitis (UP) is associated with disabling symptoms such as diarrhea, hematochezia and bowel urgency¹. Adequate therapy is crucial for symptom control and may reduce the risk of proximal disease extension. Although prior studies have explored risk factors for disease progression, they are limited by small sample sizes and have conflicting results^2,3.

Aims & Methods

We aimed to (1) assess the incidence and (2) identify risk factors for disease progression in newly diagnosed UP patients. We included all patients diagnosed with UP (inflammation ≤15 cm beyond the anal verge) between January 2000 and January 2024 in a large, non-academic hospital in the Netherlands. Data were collected from diagnosis until the end of follow-up. Disease progression was defined as endoscopic extension of UP (Montreal E1) to either left-sided (E2) or pancolitis (E3). To avoid overestimating the risk of disease progression, we used a Fine & Gray (F&G) regression model to account for patients in long-term remission who had no in-hospital follow-up. Patients who were referred back to primary care and/or had no in-hospital follow-up for ≥2 years were considered in long-term remission, which was used as a competing event in the F&G model. The cumulative incidence of disease progression was calculated at 1-, 5- and 10-years follow-up and compared to the progression rates of traditional Kaplan-Meier survival estimates.

Results

In total, 486 UP patients were included; 283 (58%) were female and median age at diagnosis was 39 years (IQR 29-53). 371 (76%) patients were in clinical remission at last follow-up. Of those, 291 (78%) were treated with topical and/or oral 5-aminosalicylates (5-ASA) and/or topical steroids; 202 (54%) required only topical and/or oral 5-ASA. 50 (10%) patients had refractory UP and required treatment with immunosuppressants or advanced therapies. During a median follow-up of 6.2 years (IQR 2.1-12.2), disease progression occurred in 112 patients (23%), of whom 80 (16%) progressed to E2 and 32 (6.6%) to E3. Median time to progression was 57 months (IQR 22-103). The cumulative incidence of disease progression was 2.8% (95% CI 1.4-4.4%) at 1 year, 13.2% (95% CI 9.9-16.4%) at 5 years and 23.9% (95% CI 19.4-28.4%) at 10 years after diagnosis and would have been overestimated with traditional Kaplan-Meier analysis (5.1% [95% CI 1.9-8.1%] at 1 year, 24.6% [95% CI 14.9-33.3%] at 5 years and 46.3% [95% CI 30.3-58.6%] at 10 years). F&G analyses demonstrated that age <18 years at diagnosis (HR 2.61, p=0.009) and the absence of steroid-free remission at 3 months (HR 1.97, p=0.005) were significant predictors for disease progression (Table 1).

Table 1. F&G risk factor assessment of proximal disease progression in UP
Variables	Hazard ratio (95% CI)	p-value
Age < 18 at diagnosis	2.61 (1.27-5.35)	0.009
Age >40 at diagnosis	0.98 (0.66-1.45)	0.92
Need for systemic steroids <1Y after diagnosis	1.54 (0.64-3.75)	0.34
Absence of steroid-free remission at 3M	1.97 (1.23-3.16)	0.005
Abbreviations. UP = ulcerative proctitis; CI = confidence interval; 3M = three months; 1Y = one year

Conclusion

In this large cohort of newly diagnosed UP patients, the 10-year cumulative incidence of disease progression was 23.9%. Most patients responded well to conventional treatment, as 60% reached clinical remission with only topical and/or oral 5-ASA and/or topical steroids. Absence of steroid-free remission at 3 months and age <18 at diagnosis were significant predictors for disease progression. Better prediction of disease progression could help identify high-risk patients who may benefit from tailored monitoring strategies, as well as low-risk patients that may be suitable for referral back to primary care.

References

1. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95(2):469-473
2. Huguet JM, Ferrer-Barceló L, Suárez P, et al. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression?. Scand J Gastroenterol. 2018;53(10-11):1286-1290.
3. Walsh E, Chah YW, Chin SM, et al. Clinical Predictors and Natural History of Disease Extension in Patients with Ulcerative Proctitis. Inflamm Bowel Dis. 2017;23(11):2035-2041.
4. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41(3):861-870.

Disclosure

RJBP, JH, RAJP, REAvD and AGLB have nothing to disclose. LAAPD has served on advisory boards for Abbvie, Janssen, Galapagos, and Pfizer, and has received independent research funding from Pfizer. ACdV has has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer.

Conference

UEG Week Berlin 2025

Topics

IBD

Submission format

Abstract

Session

Predicting outcomes in IBD (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

ESOPHAGEAL MOTILITY AND GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH TYPE 2 DIABETES OPERATED WITH GASTRIC BYPASS OR SLEEVE GASTRECTOMY, 5-YEAR RESULTS FROM THE OSEBERG STUDY

Jøran Hjelmesæth

GP: First line diagnosis and treatment

Juan Mendive

Whole diet interventions for IBS

Heidi Staudacher

The diagnosis

Bruce E. Sands

IMPACT OF DIAPHRAGMATIC RELAXING INCISION ON RECURRENCE RATE AFTER PARAESOPHAGEAL HERNIA REPAIR; 1 YEAR RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Marcus Reuterwall Hansson

INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: A RETROSPECTIVE COHORT STUDY

Alexander Bodelier

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!